The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 2, 2014, Pages 353-360

  Dalbøge, Louise S ^a   Almholt, Dorthe L C ^b   Neerup, Trine S R ^b   Vrang, Niels ^a   Jelsing, Jacob ^a   Fosgerau, Keld ^b  

^a Gubra ApS   (Denmark)

^b Zealand Pharma AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; UNCLASSIFIED DRUG; ZP 3022;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STEREOLOGY; WEIGHT REDUCTION;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CELL PROLIFERATION; GASTRINS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 84904966127     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.215293     Document Type: Article

References (46)

1. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, and Lean ME; NN8022-1807 Study Group (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606-1616.
2. Baggio LL and Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157.
3. Barrera JG, Sandoval DA, D'Alessio DA, and Seeley RJ (2011) GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 7:507-516.
4. Bock T, Pakkenberg B, and Buschard K (2003) Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52:1716-1722.
5. Bock T, Pakkenberg B, and Buschard K (2005) Genetic background determines the size and structure of the endocrine pancreas. Diabetes 54:133-137.
6. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, and Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110.
7. Dalbøge LS, Almholt DL, Neerup TS, Vassiliadis E, Vrang N, Pedersen L, Fosgerau K, and Jelsing J (2013) Characterisation of age-dependent beta cell dynamics in the male db/db mice. PLoS One 8:e82813.
8. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, and Chaudhary N, et al. (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749-757.
9. Dor Y, Brown J, Martinez OI, and Melton DA (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41-46.
10. Ellenbroek JH, Töns HA, Westerouen van Meeteren MJ, de Graaf N, Hanegraaf MA, Rabelink TJ, Carlotti F, and de Koning EJ (2013) Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia 56: 1980-1986.
11. Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, et al. (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5:209ra151.
12. Fosgerau K, Jessen L, Lind Tolborg J, Østerlund T, Schæffer Larsen K, Rolsted K, Brorson M, Jelsing J, and Skovlund Ryge Neerup T (2013) The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice. Diabetes Obes Metab 15:62-71.
13. Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, Petersen JS, Nielsen JH, and Møldrup A (2006) Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 188:481-492.
14. Inada A, Nienaber C, Katsuta H, Fujitani Y, Levine J, Morita R, Sharma A, and Bonner-Weir S (2008) Carbonic anhydrase II-positive pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth. Proc Natl Acad Sci USA 105:19915-19919.
15. Knudsen LB (2004) Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 47:4128-4134.
16. Kwon DY, Kim YS, Ahn IS, Kim da S, Kang S, Hong SM, and Park S (2009) Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J Pharmacol Sci 111:361-371.
17. Larsson LI, Ljungberg O, Sundler F, Håkanson R, Svensson SO, Rehfeld J, Stadil R, and Holst J (1973) Antor-pyloric gastrinoma associated with pancreatic nesidioblastosis and proliferation of islets. Virchows Arch A Pathol Pathol Anat 360:305-314.
18. Meier JJ (2008) Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 51:703-713.
19. Meier JJ and Bonadonna RC (2013) Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of type 2 diabetes. Diabetes Care 36 (Suppl 2): S113-S119.
20. Morisset J, Julien S, and Lainé J (2003) Localization of cholecystokinin receptor subtypes in the endocine pancreas. J Histochem Cytochem 51:1501-1513.
21. Patel V, Joharapurkar A, Gandhi T, Patel K, Dhanesha N, Kshirsagar S, Dhote V, Detroja J, Bahekar R, and Jain M (2013) Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db). J Diabetes 5:163-171.
22. Paulsen SJ, Vrang N, Larsen LK, Larsen PJ, and Jelsing J (2010) Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function. J Anat 217: 624-630.
23. Perfetti R, Zhou J, Doyle ME, and Egan JM (2000) Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141:4600-4605.
24. Perl S, Kushner JA, Buchholz BA, Meeker AK, Stein GM, Hsieh M, Kirby M, Pechhold S, Liu EH, and Harlan DM, et al. (2010) Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab 95: E234-E239.
25. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, and Jiang G, et al. (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58:2258-2266.
26. Prentki M and Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802-1812.
27. Rahier J, Guiot Y, Goebbels RM, Sempoux C, and Henquin JC (2008) Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 10 (Suppl 4):32-42.
28. Rehfeld JF, Friis-Hansen L, Goetze JP, and Hansen TV (2007) The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 7:1154-1165.
29. Roed SN, Wismann P, Underwood CR, Kulahin N, Iversen H, Cappelen KA, Schäffer L, Lehtonen J, Hecksher-Soerensen J, and Secher A, et al (2014) Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol Cell Endocrinol 382:938-949.
30. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, and Knudsen LB (2002) The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283: E745-E752.
31. Rooman I, Lardon J, and Bouwens L (2002) Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 51:686-690.
32. Saillan-Barreau C, Dufresne M, Clerc P, Sanchez D, Corominola H, Moriscot C, Guy-Crotte O, Escrieut C, Vaysse N, and Gomis R, et al. (1999) Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes 48:2015-2021.
33. Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, and Butler PC (2013) β-Cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 36: 111-117.
34. Schwasinger-Schmidt T, Robbins DC, Williams SJ, Novikova L, and Stehno-Bittel L (2013) Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats. Pharmacol Res 76:58-66.
35. Singh PK, Hota D, Dutta P, Sachdeva N, Chakrabarti A, Srinivasan A, Singh I, and Bhansali A (2012) Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 97: E2105-E2108.
36. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, and Polonsky KS (1999) Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 48:989-996.
37. Sturis J, Gotfredsen CF, Rømer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, and Carr RD, et al. (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140:123-132.
38. Suarez-Pinzon WL, Lakey JR, and Rabinovitch A (2008a) Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant 17:631-640.
39. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, and Rabinovitch A (2008b) Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281-3288.
40. Suarez-Pinzon WL, Yan Y, Power R, Brand SJ, and Rabinovitch A (2005) Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 54:2596-2601.
41. Tamaki M, Fujitani Y, Uchida T, Hirose T, Kawamori R, and Watada H (2010) Combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation. J Diabetes Investig 1: 172-183.
42. Téllez N, Joanny G, Escoriza J, Vilaseca M, and Montanya E (2011) Gastrin treatment stimulates β-cell regeneration and improves glucose tolerance in 95% pancreatectomized rats. Endocrinology 152:2580-2588.
43. Van Assche FA, Aerts L, and De Prins F (1978) A morphological study of the endocrine pancreas in human pregnancy. Br J Obstet Gynaecol 85:818-820.
44. Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Søeborg H, and Knudsen LB (2012) The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 303:E253-E264.
45. Wang Q and Brubaker PL (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45:1263-1273.
46. Xu G, Stoffers DA, Habener JF, and Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276.